Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| MASK | 3 E Network Technology Group | $2.13 | -$0.77 | -26.55% | 263.9K | $66M | $2.05$104.81 |
| TKLF | Tokyo Lifestyle | $2.17 | -$0.78 | -26.44% | 28.7K | $12M | $2.10$4.32 |
| NPT | Texxon | $12.18 | -$3.57 | -22.67% | 64.4K | $349M | $3.14$22.38 |
| CING | Cingulate | $9.07 | -$2.59 | -22.21% | 1.1M | $90M | $3.20$11.89 |
| GSIT | Gsi Technology | $6.64 | -$1.85 | -21.74% | 72.3K | $307M | $1.62$18.15 |
| SMX | Smx (Security Matters) Public | $8.73 | -$2.10 | -19.39% | 11.8K | $24M | $8.57$30,915.21 |
| RKLX | Tidal Trust II - Defiance Daily Target 2x Long Rklb ETF | $34.41 | -$7.14 | -17.18% | 1.9M | - | $3.32$78.00 |
| BIAF | bioAffinity Technologies | $2.27 | -$0.47 | -17.15% | 2.4M | $12M | $0.69$46.53 |
| GEMI | Gemini Space Station | $5.97 | -$1.14 | -16.03% | 2.2M | $837M | $5.57$45.89 |
| SQFT | Presidio Property Trust | $2.36 | -$0.44 | -15.71% | 3.2K | $4.0M | $2.17$23.00 |
| SDST | Stardust Power | $2.39 | -$0.44 | -15.55% | 69.4K | $28M | $1.43$8.43 |
| ZBAI | Atif | $4.65 | -$0.85 | -15.42% | 19.2K | $57M | $4.30$20.16 |
| CBUS | Cibus | $3.18 | -$0.50 | -13.59% | 409.8K | $243M | $1.09$4.19 |
| CLPT | ClearPoint Neuro | $9.67 | -$1.49 | -13.35% | 23.4K | $332M | $8.63$30.10 |
| NUAI | New Era Energy & Digital | $5.19 | -$0.79 | -13.29% | 4.3M | $340M | $0.32$9.45 |
| SLE | Super League Enterprise | $4.44 | -$0.68 | -13.28% | 34.8K | $6.0M | $3.25$215.42 |
| LFWD | Lifeward | $6.57 | -$0.99 | -13.16% | 9.5K | $12M | $4.14$23.04 |
| SAIL | SailPoint | $12.82 | -$1.89 | -12.85% | 227.2K | $8.3B | $11.94$24.95 |
| CTMX | CytomX Therapeutics | $4.75 | -$0.70 | -12.84% | 640.4K | $923M | $0.40$8.21 |
| DFDV | DeFi Development | $4.50 | -$0.61 | -11.94% | 611K | $153M | $0.57$53.88 |
Related Articles
Featured Article
Is This Innovative Cancer Research Biotech a Buy?
Zhiyuan Sun|May 20, 2020
Unlike many other cancer-research companies, CytomX is choosing an unconventional approach: turning tumors' high levels of protein activities against themselves. Will it be successful?
